{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01393223: Phase 2 Interventional Completed Interstitial Cystitis
(2015)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04093323: Phase 2 Interventional Recruiting HLA-A2 Positive Cells Present
(2024)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03746769: Phase 1/Phase 2 Interventional Recruiting Diabetes Mellitus, Type 1
(2019)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT01492998: Not Applicable Interventional Terminated Chronic Hepatitis C
(2010)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT01588574: Phase 2 Interventional Completed Cervical Dystonia
(2012)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04229979: Phase 3 Interventional Active, not recruiting Acute Myeloid Leukemia
(2021)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03924999: Not Applicable Interventional Completed Lipedema
(2019)
Source URL:
Class:
MIXTURE
Status:
Investigational
Class:
MIXTURE
Fallntolol is a beta-adrenergic receptor antagonist. Falintolol does not produce any noteworthy side effects and is capable of being an effective beta-blocking agent in open-angle glaucoma therapy.
Status:
Investigational
Source:
NCT01960972: Not Applicable Interventional Completed Blood Pressure
(2014)
Source URL:
Class:
MIXTURE
Status:
Investigational
Class:
MIXTURE